Erasca, a pharmaceutical company, has announced promising preliminary findings regarding its experimental drug aimed at treating pancreatic and non-small cell lung cancers.
The results from the early trials have surpassed the company's expectations, indicating potential effectiveness in these challenging cancer types.
As the trials progress, further data will be essential to confirm the drug's efficacy and safety for broader patient use.